Senate Bill Targets Prescription Drug Pricing
Recently, a bipartisan group of senators proposed new drug pricing laws aimed at addressing the role of pharmacy benefit managers (PBMs). Over the years, pharmaceutical companies have portrayed PBMs as villains in the prescription supply chain, arguing that these intermediary agents inflate prices and stifle innovation. This narrative is convenient for them, but it misses an essential truth. PBMs are, in fact, fostering competition, reducing waste, and lowering costs.
This is precisely why the pharmaceutical industry desires to sideline them.
The reality is that PBMs are quite effective—something that drug manufacturers are aware of.
In terms of government influence, the pharmaceutical sector invests more than others in lobbying and campaign contributions. In 2024, around $90 million was spent on these efforts, totaling nearly $400 million in contributions and lobbying expenses, many by former government officials now on the payroll of drug companies. The industry has also put substantial funds—about $11 billion—into advertising, effectively buying consumer attention and pressuring media narratives.
Given the fallout from the opioid crisis and the COVID-19 pandemic, Big Pharma needs scapegoats to explain rising drug prices, and they’ve found one in these lesser-known entities that most Americans may not even recognize.
However, data tells a different story. A recent study found that PBMs provide at least $145 billion in net savings each year. In comparison to manufacturer-pricing models, PBMs create an additional $192 billion of economic value. This money doesn’t vanish into corporate coffers; it circulates back into American businesses and households.
PBMs achieve these savings by negotiating with manufacturers and pharmacies. They consolidate the purchasing power of millions of consumers, securing rebates and discounts that individual plans often lack. In 2020, the rebate structure controlled by PBMs generated $51 billion in value for patients and health plans. It’s a highly competitive marketplace.
Looking ahead, PBMs are projected to save consumers around $1.2 trillion over the next decade, averaging $1,154 per year. Moreover, for every dollar spent on PBM services, the system saves $10. By directing patients toward generic and biosimilar medications, PBMs are projected to save the healthcare system $445 billion in 2023 alone. Talk about efficiency.
Perhaps even more crucially, PBMs enhance health outcomes. When patients can afford their medications, they are more likely to take them, resulting in fewer hospital visits and emergency care. Programs driven by PBMs have led to increases in medication adherence by 16% and a 10% drop in inpatient hospitalizations.
Having healthier Americans is, of course, beneficial—not only for individuals but also for a productive economy.
By minimizing costs for insurance premiums and medications through public programs, PBMs help save taxpayers money—an estimated $47 billion annually. Additionally, they promote quicker access to new treatments during the early stages of patents, thereby supporting, not hindering, drug innovation.
Currently, PBMs manage around 95% of retail prescriptions for 91% of health plan participants, a testament to their effectiveness. Companies seeking free market solutions value PBMs, as they enable affordable coverage without compromising quality.
It’s clear that PBMs are delivering results, which is precisely why they are under scrutiny from drug manufacturers. The industry’s campaign to reframe PBMs as problematic rather than beneficial is revealing.
For instance, a report from the Federal Trade Commission during the Biden administration depicted PBMs negatively, yet even FTC Commissioner Melissa Holyoak expressed skepticism about the report’s conclusions. She emphasized that it overlooked substantial evidence of savings provided by PBMs, warning against politicizing the issue.
Although some lawmakers seem to be buying into Big Pharma’s narrative, various proposals at the federal and state levels could undermine PBMs. Analyses from entities like the Brookings Institution suggest that targeting PBMs won’t lower costs; it will simply reduce their negotiating power with manufacturers.
Such measures wouldn’t qualify as reform but could instead amount to malpractice. To dismantle the very mechanism that enforces price discipline is akin to prioritizing Big Pharma interests over patient needs.
This battle is not merely a matter of patient care versus intermediaries; it’s fundamentally about competition versus monopoly, market discipline versus unchecked corporate power.
PBMs negotiate better drug options and deliver real value. When an industry as powerful as pharmaceuticals is desperate to eliminate them, it’s clear that there’s more at stake than meets the eye. That realization alone should be telling.
